Literature DB >> 27558979

Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.

Liv Mundal1, Marit B Veierød2,3, Thomas Halvorsen4, Kirsten B Holven2,5, Leiv Ose2, Per Ole Iversen2,6, Grethe S Tell7,8, Trond P Leren9, Kjetil Retterstøl1,2.   

Abstract

Background Familial hypercholesterolaemia increases the risk for cardiovascular disease. The primary aim of the present study was to describe sex differences in incidence and prevalence of cardiovascular disease leading to hospitalisation in a complete cohort of genotyped familial hypercholesterolaemia patients. Design and methods In this registry study data on 5538 patients with verified genotyped familial hypercholesterolaemia were linked to data on all Norwegian cardiovascular disease hospitalisations, and hospitalisations due to pre-eclampsia/eclampsia, congenital heart defects and diabetes. Results During 1994-2009 a total of 1411 of familial hypercholesterolaemia patients were hospitalised, and ischaemic heart disease was reported in 90% of them. Mean (SD) age at first hospitalisation and first re-hospitalisation was 45.1 (16.5) and 47.6 (16.3) years, respectively, with no sex differences ( P = 0.66 and P = 0.93, respectively). More men (26.9%) than women (24.1%) with familial hypercholesterolaemia were hospitalised ( P = 0.02). The median (25th-75th percentile) number of hospital admissions was four (two to seven) per familial hypercholesterolaemia patient, with no sex differences ( P = 0.87). Despite having familial hypercholesterolaemia at the time of hospitalisation, the diagnosis of familial hypercholesterolaemia was registered in only 45.7% of the patients at discharge. Conclusion Most cardiovascular disease hospitalisations were due to ischaemic heart disease. Familial hypercholesterolaemia patients were first time hospitalised at age 45.1 years, with no significant sex differences in age, which are important novel findings. The awareness and registration of the familial hypercholesterolaemia diagnosis during the hospital stays were disturbingly low.

Entities:  

Keywords:  Familial hypercholesterolaemia; cardiovascular disease; registries

Mesh:

Year:  2016        PMID: 27558979     DOI: 10.1177/2047487316666371

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  4 in total

Review 1.  Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care.

Authors:  Sujana Balla; Eson P Ekpo; Katherine A Wilemon; Joshua W Knowles; Fatima Rodriguez
Journal:  Curr Atheroscler Rep       Date:  2020-08-20       Impact factor: 5.113

2.  Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration.

Authors:  Matthew I Bellgard; Caroline E Walker; Kathryn R Napier; Leanne Lamont; Adam A Hunter; Lee Render; Maciej Radochonski; Jing Pang; Annette Pedrotti; David R Sullivan; Karam Kostner; Warrick Bishop; Peter M George; Richard C O'Brien; Peter M Clifton; Frank M Van Bockxmeer; Stephen J Nicholls; Ian Hamilton-Craig; Hugh Js Dawkins; Gerald F Watts
Journal:  J Atheroscler Thromb       Date:  2017-03-24       Impact factor: 4.928

Review 3.  Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.

Authors:  Ivan Pećin; Merel L Hartgers; G Kees Hovingh; Ricardo Dent; Željko Reiner
Journal:  Eur J Prev Cardiol       Date:  2017-06-23       Impact factor: 7.804

4.  Lower risk of smoking-related cancer in individuals with familial hypercholesterolemia compared with controls: a prospective matched cohort study.

Authors:  Henriette W Krogh; Karianne Svendsen; Jannicke Igland; Liv J Mundal; Kirsten B Holven; Martin P Bogsrud; Trond P Leren; Kjetil Retterstøl
Journal:  Sci Rep       Date:  2019-12-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.